Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook

Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $426 million versus the consensus estimate of $427.94 million.

Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance